Changing dopamine agonist treatment in Parkinson's disease: experiences with switching to pramipexole.

Abstract

1202 patients suffering from Parkinson's disease switched from other dopamine agonists to pramipexole under open conditions either abruptly or in an overlapping, gradual manner. Mostly insufficient effectiveness motivated the switch. The investigators gave equal preference to either an abrupt or an overlapping switch to pramipexole in this observational study. There was a tendency in favour of the overlapping switch procedure in those patients who were on a relatively higher dose of a dopamine agonist before the switch. The switch was performed because the investigators expected the effect of pramipexole on tremor, motor functions and depression/anhedonia to be better compared with previous dopamine agonists. The main reasons for switching to pramipexole (anti-tremor effect, anti-depressive/anti-anhedonic effect) as given by the physicians at baseline came up to expectations. The switch to pramipexole mostly yielded further improvements irrespective of the mode of switching.

• Authors: H Reichmann, P Odin, H M Brecht, J Köster, P H Kraus
• Journal: Journal of neural transmission. Supplementum (J Neural Transm Suppl) Issue 71 Pg. 17-25 ( 2006) ISSN: 0303-6995 [Print] Austria
• PMID: 17447411 (Publication Type: Comparative Study, Evaluation Study, Journal Article)

Chemical References

• Benzothiazoles
• Dopamine Agonists
• Pramipexole

Topics

• Aged
• Benzothiazoles (administration & dosage, agonists)
• Dopamine Agonists (administration & dosage, adverse effects)
• Female
• Humans
• Male
• Motor Activity (drug effects)
• Parkinsonian Disorders (drug therapy, physiopathology)
• Pramipexole
• Product Surveillance, Postmarketing
• Prospective Studies
• Psychomotor Performance (drug effects)
• Retrospective Studies
• Severity of Illness Index
• Tremor (chemically induced)